New discoveries are increasing the number of biomarker/drug associations at an unprecedented rate. It is more important than ever for cancer patients to have comprehensive molecular testing on their tumors.
Caris molecular profiling utilizes a comprehensive approach to assess DNA, RNA and proteins to reveal a molecular blueprint to guide more precise and individualized treatment decisions from among 75+ FDA-approved therapies.
Sufficient tumor content (>20% tumor nuclei) must be present to complete all analysis. If you have questions, please contact Customer Support at (888) 979-8669.
Tumor content: >20% tumor nuclei
Paraffin Block (Preferred)
Formalin fixed tissue block (including core-needle biopsies, fine-needle aspirates or malignant fluid)
10% neutral buffered formalin
Four to six (4-6) biopsies with 18 gauge needle preferred
Six to ten (6-10) biopsies with 22 needle accepted
Multi-Omic Biomarker Analysis
DNA RNA Protein
NGS (WES & WTS) IHC ISH PyroSeq
Genes | Depth/Read
22,000 | 800x WES/23Mx WTS
Whole Exome Sequencing (WES) DNA
SNV INDEL CNA Karyotyping
Whole Transcriptome Sequencing (WTS) RNA
Fusion Variant Transcript Gene Expression
HRD* gLOH MSI TMB
20% Tumor (NGS) | 1 Slide per IHC/ISH
*Not available in all locations.
The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.
Whole Exome Sequencing (WES)
Whole Transcriptome Sequencing (WTS)
Select tumor type to see specific tests to be performed.
Place an order today for a comprehensive, personalized Caris profiling report.